February 20, 2026
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval to zanidatamab (Ziihera, Jazz Pharmaceuticals) for the treatment of adults with advanced biliary tract […]
February 20, 2026
The FDA has approved topical difamilast for treating mild-to-moderate atopic dermatitis (AD) in adults and children aged 2 years or older, according to a press release […]
February 18, 2026
Amivantamab and hyaluronidase-lpuj (Rybrevant Faspro, Johnson & Johnson) is now approved as a once-monthly subcutaneous injection for the first-line treatment of epidermal growth factor receptor (EGFR)-mutated […]
February 18, 2026
The National Institute for Health and Care Excellence (NICE) has published final guidance recommending that most people newly diagnosed with type 2 diabetes be offered SGLT2 […]
February 13, 2026
The European Medicines Agency’s (EMA’s) Pharmacovigilance Risk Assessment Committee (PRAC) has recommended that levamisole-containing medicines be withdrawn from the EU market because their benefits no longer […]
February 12, 2026
The FDA has approved a first-of-its-kind wearable electrical device — Optune Pax (Novocure) — for patients with locally advanced pancreatic cancer, in combination with gemcitabine and […]
February 11, 2026
The US Food and Drug Administration has approved pembrolizumab (Keytruda, Merck), as well as its subcutaneous formulation pembrolizumab and berahyaluronidase (Keytruda Qlex, Merck), in combination with […]
February 11, 2026
The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending durvalumab (Imfinzi, AstraZeneca), given with gemcitabine and cisplatin before surgery and […]
July 7, 2025
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved nogapendekin alfa inbakicept (Anktiva, ImmunityBio) for use in adults with carcinoma in situ (CIS) non-muscle-invasive bladder […]